fostamatinib 100 MG Oral Tablet [Tavalisse]
fostamatinib
RxCUI: 2044928
What the CMS Formulary Data Shows for fostamatinib 100 MG Oral Tablet [Tavalisse]
Per the CMS 2026 Part D formulary file, fostamatinib 100 MG Oral Tablet [Tavalisse] (RxNorm concept RXCUI 2044928, generic name fostamatinib) appears on 22 distinct formulary files spanning 226 Medicare Part D plan offerings - 4.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.5.
Real-world access to fostamatinib 100 MG Oral Tablet [Tavalisse] depends on utilization management as much as tier placement: 95.5% of covering formularies require prior authorization. 0% require step therapy. 86.4% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 486 Part D beneficiaries filled fostamatinib 100 MG Oral Tablet [Tavalisse] in 2023, with total plan-and-beneficiary spending of $39,505,314 and an average per-beneficiary annual cost of $81,286.65. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry fostamatinib 100 MG Oral Tablet [Tavalisse] today.
Coverage Details
- Formularies covering
- 22
- Plans covering
- 226
- Coverage rate
- 4.5%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 95.5% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 86.4% of formularies
2023 Medicare Spending
- Beneficiaries
- 486
- Total spending
- $39,505,314
- Avg per beneficiary
- $81,286.65
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering fostamatinib 100 MG Oral Tablet [Tavalisse]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is fostamatinib 100 MG Oral Tablet [Tavalisse] covered by Medicare Part D?
Yes, fostamatinib 100 MG Oral Tablet [Tavalisse] is covered by 226 Medicare Part D plans (4.5% of all Part D formularies).
What tier is fostamatinib 100 MG Oral Tablet [Tavalisse] on Medicare Part D plans?
fostamatinib 100 MG Oral Tablet [Tavalisse] averages Tier 4.5 across Part D plans, ranging from Tier 1 to Tier 5.
Does fostamatinib 100 MG Oral Tablet [Tavalisse] require prior authorization?
95.5% of Part D formularies require prior authorization for fostamatinib 100 MG Oral Tablet [Tavalisse]. Step therapy: 0%. Quantity limits: 86.4%.
How much does Medicare spend on fostamatinib 100 MG Oral Tablet [Tavalisse]?
In 2023, total Medicare Part D spending on fostamatinib 100 MG Oral Tablet [Tavalisse] was $39,505,314, covering 486 beneficiaries. The average spend per beneficiary was $81,286.65.
Read our methodology - how this data is sourced, computed, and verified.